Document is current
Any future updates will be listed below
-
Authors
Jalatyan, Tatevik https://orcid.org/0000-0002-8548-7916
Aznauryan, Erik https://orcid.org/0000-0001-7666-7299
Hasan, Rokib
Vardanyan, Valeri
Nersisyan, Stepan https://orcid.org/0000-0002-8830-4679
Thompson, David B.
Davidsohn, Noah
Thomas, Sanya
van Haren, Simon
Tam, Jenny https://orcid.org/0000-0002-3767-7205
Milanova, Denitsa
Church, George M. https://orcid.org/0000-0003-3535-2076
Nersisyan, Lilit https://orcid.org/0000-0001-8525-420X
- License Information
-
More Information
Article History
Received: 29 September 2024
Revised: 12 May 2025
Accepted: 25 June 2025
First Online: 8 July 2025
Competing interests
: Harvard University has filed for patent protection on DC and HDF-enriched AAV variants described herein, and EA, DM, and GMC are named as co-inventors on the patent. At the time of study, EA performed consulting services, and RH and ND were employees and held equity in Rejuvenate Bio. DM and DBT are full-time employees and hold equity in Medici Therapeutics, Inc. For a complete list of GMC's financial interests, see . The remaining authors declare no competing interests.
: All procedures involving Beagle dogs in this study were conducted in accordance with the USDA Animal Welfare Act (9 CFR, Parts 1, 2, and 3) and the Guide for Care and Use of Laboratory Animals (ILAR publication, 2011). The protocols were approved by the institutional ethical review board at Absorption Systems California, LLC (ASC), and conducted under the authority of the Project License issued by ASC’s compliance office. The animals were housed in compliance with ethical standards, provided with a certified laboratory diet (5007 laboratory canine diet from LabDiet), and had access to water ad libitum. The study followed the Standard Operating Procedures established at ASC, ensuring a high standard of care and scientific integrity throughout the experiment.
